Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Acute Respiratory Failure
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypogonadism, Male, Cancer, Fatigue
Interventions: testosterone 1.62% gel, placebo gel; Drug · Other
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 55 Years and older · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Augusta, Georgia • Boston, Massachusetts • Seattle, Washington

Conditions: Gender Identity, Gender Dysphoria in Adolescents and Adults, Headache, Transgender
Interventions: Testosterone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 20 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Burns
Interventions: testosterone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Anxiety Disorder, Depression, Genetic Disorder, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Electronic Health Record Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypogonadism
Interventions: Oral Testosterone Undecanoate; Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Torrance, California • Orlando, Florida

Conditions: Hypogonadism, Erectile Dysfunction
Interventions: Testim®, Placebo Testim®, Viagra®; Drug · Other
Lead sponsor: Mohit Khera; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Testosterone
Interventions: Heart and Soil's Whole Package; Dietary Supplement
Lead sponsor: Efforia, Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
Interventions: Lutetium Lu 177-PSMA-617, Pembrolizumab; Drug · Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions: androgel, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 31 Years to 60 Years · Male only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypogonadism
Interventions: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose); Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • San Antonio, Texas

Conditions: Hypogonadism
Interventions: Nasobol®, Androderm® (Positive Control); Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Abiraterone Acetate, Apalutamide, Cabazitaxel, Carboplatin, Ipilimumab, Laboratory Biomarker Analysis, Prednisone; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 3
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: AIDS Wasting Syndrome
Interventions: Testosterone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Testosterone's Effects on Threat Perception/Response
Interventions: Testosterone; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Panhypopituitarism
Interventions: Not listed
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypogonadism, Diabetes
Interventions: Testosterone gel, placebo; Drug
Lead sponsor: Diabetes Center of the Southwest; Other
Eligibility: 35 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Midland, Texas

Conditions: Abuse of Anabolic Steroids
Interventions: Testosterone; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypogonadotropic Hypogonadism
Interventions: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more

Conditions: Prostatic Neoplasms
Interventions: Leuprolide acetate; Drug
Lead sponsor: Abbott; Industry
Eligibility: Male only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 55
States / cities: Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 49 more

Conditions: ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Transgender Persons
Interventions: Progesterone 200 MG, Placebo; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hypogonadism, Hypogonadism, Male
Interventions: Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Tacoma, Washington

Search by objective public record fields.

Outcomes of Mechanically Ventilated Patients With Low Serum Testosterone

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

Puberty, Testosterone, and Brain Development

Randomized Study of Testosterone and Progressive Resistance Exercise in Men With Burn Injury

Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes

The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate

Testosterone for Penile Rehabilitation After Radical Prostatectomy

Evaluating Heart & Soil's Whole Package on Men's Health

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

AIDS Wasting in Women: Anabolic Effects of Testosterone

Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance

Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism

Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes

Intranasal Delivery of Testosterone and Its Effect on Doping Markers

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride